These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 36593576)

  • 1. COVID-19 and non-alcoholic fatty liver disease: Biological insights from multi-omics data.
    Pirola CJ; Sookoian S
    Liver Int; 2023 Mar; 43(3):580-587. PubMed ID: 36593576
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tissue-specific pathways and networks underlying sexual dimorphism in non-alcoholic fatty liver disease.
    Kurt Z; Barrere-Cain R; LaGuardia J; Mehrabian M; Pan C; Hui ST; Norheim F; Zhou Z; Hasin Y; Lusis AJ; Yang X
    Biol Sex Differ; 2018 Oct; 9(1):46. PubMed ID: 30343673
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Non-alcoholic Fatty Liver Disease and COVID-19 Susceptibility and Outcomes: a Korean Nationwide Cohort.
    Yoo HW; Jin HY; Yon DK; Effenberger M; Shin YH; Kim SY; Yang JM; Kim MS; Koyanagi A; Jacob L; Smith L; Yoo IK; Shin JI; Lee SW
    J Korean Med Sci; 2021 Oct; 36(41):e291. PubMed ID: 34697932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. From sugar to liver fat and public health: systems biology driven studies in understanding non-alcoholic fatty liver disease pathogenesis.
    Moore JB
    Proc Nutr Soc; 2019 Aug; 78(3):290-304. PubMed ID: 30924429
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).
    Saeed A; Dullaart RPF; Schreuder TCMA; Blokzijl H; Faber KN
    Nutrients; 2017 Dec; 10(1):. PubMed ID: 29286303
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multiomics biomarkers for the prediction of nonalcoholic fatty liver disease severity.
    Pirola CJ; Sookoian S
    World J Gastroenterol; 2018 Apr; 24(15):1601-1615. PubMed ID: 29686467
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Understanding the Role of the Gut Microbiome and Microbial Metabolites in Non-Alcoholic Fatty Liver Disease: Current Evidence and Perspectives.
    Vallianou N; Christodoulatos GS; Karampela I; Tsilingiris D; Magkos F; Stratigou T; Kounatidis D; Dalamaga M
    Biomolecules; 2021 Dec; 12(1):. PubMed ID: 35053205
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bile acids profile, histopathological indices and genetic variants for non-alcoholic fatty liver disease progression.
    Nimer N; Choucair I; Wang Z; Nemet I; Li L; Gukasyan J; Weeks TL; Alkhouri N; Zein N; Tang WHW; Fischbach MA; Brown JM; Allayee H; Dasarathy S; Gogonea V; Hazen SL
    Metabolism; 2021 Mar; 116():154457. PubMed ID: 33275980
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Research progress of omics biomarkers for nonalcoholic fatty liver disease].
    Wang L; Liu XE; Zhuang H
    Zhonghua Gan Zang Bing Za Zhi; 2021 Jun; 29(6):604-608. PubMed ID: 34225440
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.
    McGlinchey AJ; Govaere O; Geng D; Ratziu V; Allison M; Bousier J; Petta S; de Oliviera C; Bugianesi E; Schattenberg JM; Daly AK; Hyötyläinen T; Anstee QM; Orešič M
    JHEP Rep; 2022 May; 4(5):100477. PubMed ID: 35434590
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discovery and Targeting of the Signaling Controls of
    Schwartz BE; Rajagopal V; Smith C; Cohick E; Whissell G; Gamboa M; Pai R; Sigova A; Grossman I; Bumcrot D; Sasidharan K; Romeo S; Sehgal A; Pingitore P
    Cells; 2020 Oct; 9(10):. PubMed ID: 33036387
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NAFLD risk alleles in PNPLA3, TM6SF2, GCKR and LYPLAL1 show divergent metabolic effects.
    Sliz E; Sebert S; Würtz P; Kangas AJ; Soininen P; Lehtimäki T; Kähönen M; Viikari J; Männikkö M; Ala-Korpela M; Raitakari OT; Kettunen J
    Hum Mol Genet; 2018 Jun; 27(12):2214-2223. PubMed ID: 29648650
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GWAS and enrichment analyses of non-alcoholic fatty liver disease identify new trait-associated genes and pathways across eMERGE Network.
    Namjou B; Lingren T; Huang Y; Parameswaran S; Cobb BL; Stanaway IB; Connolly JJ; Mentch FD; Benoit B; Niu X; Wei WQ; Carroll RJ; Pacheco JA; Harley ITW; Divanovic S; Carrell DS; Larson EB; Carey DJ; Verma S; Ritchie MD; Gharavi AG; Murphy S; Williams MS; Crosslin DR; Jarvik GP; Kullo IJ; Hakonarson H; Li R; ; Xanthakos SA; Harley JB
    BMC Med; 2019 Jul; 17(1):135. PubMed ID: 31311600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of Multi-omics Data from Mouse Diversity Panel Highlights Mitochondrial Dysfunction in Non-alcoholic Fatty Liver Disease.
    Chella Krishnan K; Kurt Z; Barrere-Cain R; Sabir S; Das A; Floyd R; Vergnes L; Zhao Y; Che N; Charugundla S; Qi H; Zhou Z; Meng Y; Pan C; Seldin MM; Norheim F; Hui S; Reue K; Lusis AJ; Yang X
    Cell Syst; 2018 Jan; 6(1):103-115.e7. PubMed ID: 29361464
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of omics in the pathophysiology, diagnosis and treatment of non-alcoholic fatty liver disease.
    Perakakis N; Stefanakis K; Mantzoros CS
    Metabolism; 2020 Oct; 111S():154320. PubMed ID: 32712221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. IL-6/STAT3 axis dictates the PNPLA3-mediated susceptibility to non-alcoholic fatty liver disease.
    Park J; Zhao Y; Zhang F; Zhang S; Kwong AC; Zhang Y; Hoffmann HH; Bushweller L; Wu X; Ashbrook AW; Stefanovic B; Chen S; Branch AD; Mason CE; Jung JU; Rice CM; Wu X
    J Hepatol; 2023 Jan; 78(1):45-56. PubMed ID: 36049612
    [TBL] [Abstract][Full Text] [Related]  

  • 17. COVID-19 and non-alcoholic fatty liver disease: Two intersecting pandemics.
    Portincasa P; Krawczyk M; Smyk W; Lammert F; Di Ciaula A
    Eur J Clin Invest; 2020 Oct; 50(10):e13338. PubMed ID: 32589264
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low hepatic copper content and PNPLA3 polymorphism in non-alcoholic fatty liver disease in patients without metabolic syndrome.
    Stättermayer AF; Traussnigg S; Aigner E; Kienbacher C; Huber-Schönauer U; Steindl-Munda P; Stadlmayr A; Wrba F; Trauner M; Datz C; Ferenci P
    J Trace Elem Med Biol; 2017 Jan; 39():100-107. PubMed ID: 27908400
    [TBL] [Abstract][Full Text] [Related]  

  • 19. COVIDomics: The Proteomic and Metabolomic Signatures of COVID-19.
    Costanzo M; Caterino M; Fedele R; Cevenini A; Pontillo M; Barra L; Ruoppolo M
    Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269564
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease - novel insights into cellular communication circuits.
    Peiseler M; Schwabe R; Hampe J; Kubes P; Heikenwälder M; Tacke F
    J Hepatol; 2022 Oct; 77(4):1136-1160. PubMed ID: 35750137
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.